Clinical trials: Treatment-resistant Schizophrenia
Schizophrenia, Transcranial Magnetic Stimulation
Personalized Dual-target RTMS for Patients with Refractory Schizophrenia
The goal of this clinical trial is to evaluate the efficacy of personalized dual-target rTMS for treating patients with refractory schizophrenia and to investigate its underlying neural mechanisms using functional MRI.
- Conditions
- Schizophrenia, Transcranial Magnetic Stimulation, Functional Magnetic Resonance Imaging (fMRI)
- Trial name
- NCT06732817
- Testing
- Active rTMS was administered using a transcranial magnetic stimulator (Rapid2; MagStim).
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Medical University
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Berberine as Adjuvant Treatment for Schizophrenia Patients
One double-blind, randomized, placebo-controlled trial is designed to examine whether berberine added to current antipsychotic drugs could produce significantly greater efficacy in reducing atypical antipsychotic-induced…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Metabolic Syndrome x
- Trial name
- BER (NCT02983188)
- Testing
- Berberine, Antipsychotic Agents
- Where
- Hong Kong
- Volunteers
- 113 people
- Sponsor
- The University of Hong Kong
Schizophrenia; Negative Type
Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia
Schizophrenia is a complex, challenging, and heterogeneous psychiatric condition, affecting up to 0.5% of the population and responsible for nearly 2% of all Canadian health-care expenditure.
- Trial name
- NCT01725334
- Testing
- Deep Brain Stimulation
- Where
- Canada
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Electroconvulsive Therapy in Clozapine-resistant Schizophrenia
Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia…
- Trial name
- NCT02159001
- Testing
- electroconvulsive therapy
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Niuvanniemi Hospital
Hallucinations, Verbal Auditory
Transcranial Magnetic Stimulation (TMS) for Patients With Treatment Resistant Auditory Verbal Hallucination
This study will evaluate the effect of repetitive transcranial magnetic stimulation (rTMS) in schizophrenia with treatment resistant auditory verbal hallucination
- Trial name
- TMS (NCT03762746)
- Testing
- Transcranial Magnetic Stimulation, Control
- Where
- Indonesia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Schizophrenia
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
The aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or schizoaffective disorder.
- Trial name
- HDL (NCT01569659)
- Testing
- Lurasidone
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Northwestern University
Treatment-resistant Schizophrenia
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
This study includes two main components: the first screening phase and the second clinical intervention phase. During the screening phase, subjects with poor response to clozapine are carefully evaluated by chart-review and…
- Trial name
- M1106 (NCT01105481)
- Testing
- Amisulpride add-on
- Where
- 2 sites in Taiwan
- Volunteers
- 273 people
- Sponsor
- National Health Research Institutes, Taiwan
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Treatment-Refractory Schizophrenia
Deep Brain Stimulation for Psychosis
There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment.
- Trial name
- NCT06257056
- Testing
- Abbott Laboratories Infinity™ implantable deep brain stimulation system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bradley Lega
Obesity, Metabolic Syndrome X
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum.
- Conditions
- Obesity, Metabolic Syndrome X, Drug-induced Obesity, Schizophrenia
- Trial name
- TAO (NCT01794429)
- Testing
- Exenatide
- Where
- Denmark
- Volunteers
- 45 people
- Sponsor
- Bjorn H. Ebdrup
Schizophrenia, Treatment Resistant Schizophrenia
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current…
- Trial name
- MECT-RESIST (NCT06456983)
- Testing
- maintenance electroconvulsive therapy (mECT)
- Where
- 14 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Auditory Hallucination
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication…
- Conditions
- Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
- Trial name
- NCT05299749
- Testing
- stg-rt-fMRI-Neurofeeback
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Boston VA Research Institute, Inc.
Insulin Resistance, Body Composition
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
This project aims to a) evaluate the effects of haloperidol, olanzapine, and risperidone in combination with valproate on insulin secretion and insulin actions, b) evaluate medication effects on abdominal fat, total body fat and…
- Trial name
- DepIVGTT (NCT00552500)
- Testing
- Depakote (valproate)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Treatment Refractory
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
The etiology of schizophrenia remains unclear In recent one decade, hypofunction of N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.
- Trial name
- NCT01251055
- Testing
- GlyT-1 inhibitor-1
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Schizophrenia
Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.
- Trial name
- NCT00328367
- Testing
- aripiprazole
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Seoul National University Hospital
Schizophrenia
D-serine in Schizophrenia
This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.
- Trial name
- DSRSZ (NCT03702933)
- Testing
- D-serine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Herzog Hospital
Schizophrenia, Auditory Hallucinations
A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine
The primary outcome of this study is to evaluate the effects of low frequency subthreshold repetitive Transcranial Magnetic Stimulation applied to the left temporoparietal cortex of patients with refractory schizophrenia on the…
- Trial name
- NCT01015001
- Testing
- (1Hz) rTMS applied over the left temporoparietal cortex
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Schizophrenia, Hallucinations, Auditory
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
The INTRUDE trial aims at assessing the efficacy of an fMRI-based neurofeedback procedure on drug-resistant auditory hallucinations.
- Conditions
- Schizophrenia, Hallucinations, Auditory, Hallucinations, Visual
- Trial name
- INTRUDE (NCT04798131)
- Testing
- Active neurofeedback procedure
- Where
- France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Lille
Metabolic Syndrome
Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. Until now, the lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d.
- Trial name
- NCT02751307
- Testing
- metformin 500 mg, clozapine 100 mg
- Volunteers
- 55 people
- Sponsor
- Taipei Medical University WanFang Hospital
Schizophrenia, Forensic Psychiatry
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service.
- Conditions
- Schizophrenia, Forensic Psychiatry, Outcome Measure, Violence
- Trial name
- D-FOREST (NCT05074732)
- Where
- Ireland
- Volunteers
- 350 people
- Sponsor
- Health Service Executive, Ireland